These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6472539)

  • 21. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man.
    Bagdade J; Casaretto A; Albers J
    J Lab Clin Med; 1976 Jan; 87(1):38-48. PubMed ID: 173766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients.
    Elisaf M; Bairaktari E; Katopodis K; Pappas M; Sferopoulos G; Tzallas C; Tsolas O; Siamopoulos KC
    Am J Nephrol; 1998; 18(5):416-21. PubMed ID: 9730566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Results of a multicenter study on the effect on serum triglycerides and cholesterol administration of carnitine in chronic uremia patients undergoing periodic hemodialysis treatment].
    Toigo G; Situlin R; Dardi F; Bazzato G; Vasile A; Tesio F; Ciman M; Guarnieri GF
    G Clin Med; 1982; 63(11-12):841-9. PubMed ID: 7182204
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients.
    Ibels SL; Reardon MF; Nestel PJ
    J Lab Clin Med; 1976 Apr; 87(4):648-58. PubMed ID: 775004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid metabolism in uremia: effect of regular hemofiltration and hemodialysis treatment.
    Henning HV; Balusek E
    J Dial; 1977; 1(6):595-605. PubMed ID: 608870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Protective role of carnitine in acetate metabolism of patients with uremia treated by hemodialysis].
    Wanic-Kossowska M
    Pol Arch Med Wewn; 1997 Jun; 97(6):534-40. PubMed ID: 9441289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of dialysate composition on the lipid response to L-carnitine supplementation.
    Zilleruelo G; Novak M; Hsia SL; Goldberg R; Abitbol C; Monkus E; Strauss J
    Kidney Int Suppl; 1989 Nov; 27():S259-63. PubMed ID: 2699997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
    Elshamaa MF; Elghoroury EA; Helmy A
    Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism.
    Goldberg A; Sherrard DJ; Brunzell JD
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1173-82. PubMed ID: 400739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of L-carnitine supplementation in hemodialysis patients.
    Veselá E; Racek J; Trefil L; Jankovy'ch V; Pojer M
    Nephron; 2001 Jul; 88(3):218-23. PubMed ID: 11423752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of L-carnitine on arrhythmias during hemodialysis.
    Suzuki Y; Narita M; Yamazaki N
    Jpn Heart J; 1982 May; 23(3):349-59. PubMed ID: 6178854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia.
    Moberly JB; Attman PO; Samuelsson O; Johansson AC; Knight-Gibson C; Alaupovic P
    Miner Electrolyte Metab; 1999; 25(4-6):258-62. PubMed ID: 10681649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced platelet apoptosis in chronic uremic patients.
    Li M; Wang Z; Ma T; Lu G; Yan R; Zhao L; Deng K; Dai K
    Ren Fail; 2014 Jul; 36(6):847-53. PubMed ID: 24655051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response patterns to DL-carnitine in patients on maintenance haemodialysis.
    Chan MK; Persaud JW; Varghese Z; Baillod RA; Moorhead JF
    Nephron; 1982; 30(3):240-3. PubMed ID: 7099336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension.
    Noris M; Benigni A; Boccardo P; Aiello S; Gaspari F; Todeschini M; Figliuzzi M; Remuzzi G
    Kidney Int; 1993 Aug; 44(2):445-50. PubMed ID: 8377388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet aggregation and prostaglandin metabolism in uremic patients.
    Pietrzak I; Komarnicki M; Zaremba-Drobnik D
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S111-4. PubMed ID: 11576934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelets and platelet function in patients with chronic uremia on maintenance hemodialysis.
    Jørgensen KA; Ingeberg S
    Nephron; 1979; 23(5):233-6. PubMed ID: 481658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
    Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic heparinization of uremic patients and its effects on blood lipids and on in vitro toxicity of the plasma.
    Wessel-Aas T; Christophersen B
    Clin Nephrol; 1982 Sep; 18(3):135-40. PubMed ID: 7140025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of oral carnitine supplementation on disturbances of lipid metabolism in the uremic rat.
    Basile C; Lacour B; Di Giulio S; Drüeke T
    Nephron; 1985; 39(1):50-4. PubMed ID: 3969191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.